PO.IM01.11 · 免疫学

Tumoral IL-33/ST2 signaling drives immune escape through reduced antigen presentation

编号 2799 展板 4 时间 4/20 02:00–05:00 区域 Section 7 主讲 Alyssa Mauri Cornista, AA;BS

分会场 Immune Checkpoints

查看完整资料下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Alyssa Mauri Cornista¹, Tao Yu², Zhuolong Zhou², Nikša Roki¹, Alberto Sigler¹, David M. Suissa¹, Haniyeh Eyvani³, George E. Sandusky⁴, Rimpi Khurana⁵, Yan Guo⁶, Molly Dalzell¹, Shyamananda Singh Mayengbam⁷, Prasenjit Dey⁷, Christine Rafie¹, Erietta Stelekati⁸, Jashodeep Datta⁹, Saratchandra S. Khumukcham¹⁰, Jatin Roper¹⁰, Nivedh Paluvoi¹¹, Sandro Satta¹², Daniel Bilbao Cortes¹², Alejandro Villarino⁸, Kevin Van der Jeught⁸

¹Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, FL,²Medical and Molecular Genetics; Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN,³Medical and Molecular Genetics, University of Miami Miller School of Medicine, Miami, FL,⁴Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN,⁵Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL,⁶Sylvester Comprehensive Cancer Center; Public Health and Sciences, University of Miami Miller School of Medicine, Miami, FL,⁷Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY,⁸Microbiology and Immunology; Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL,⁹Division of Surgical Oncology, Dewitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL,¹⁰Medicine, Division of Gastroenterology; Pharmacology and Cancer Biology, Duke University Medical Center, Durham, NC,¹¹Division of Surgical Oncology, Dewitt Daughtry Department of Surgery, University of Miami Miller School of Medicine, Miami, FL,¹²Sylvester Comprehensive Cancer Center; Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, FL

摘要 Abstract

The majority (up to 85%) of colorectal cancer (CRC) patients have a microsatellite stable (MSS) tumor phenotype, which is a poor responder to immune checkpoint blockade (ICB). Therefore, there is a need to identify novel checkpoints in the tumor microenvironment, such as ST2 (Stimulation 2, IL33 receptor). We demonstrated ST2 to be prominently expressed on human tumor cells, especially MSS tumors, through multiplex immunofluorescence staining of CRC patient samples and publicly available datasets. Using CRC patient-derived organoids, we established that activation of tumoral IL33/ST2 signaling conferred tumor cell protection from T cell-mediated killing. To investigate the mechanistic basis of how tumor cells escape T cell killing, we used colonoscopy-induced, orthotopic murine tumors. We uncovered that IL33/ST2 signaling reduced antigen presentation, driven by reduced immunoproteasome activity. Removing tumoral ST2 signaling using CRISPR/Cas9-gene editing leads to significant tumor growth control and increased infiltration of T cells with a reduced terminally exhausted phenotype. Altogether, these findings indicate ST2 as a potential, novel checkpoint target on tumor cells to enlarge the pool of patients benefiting from ICB.

利益披露 Disclosure

A. Cornista, None.. T. Yu, None.. Z. Zhou, None.. N. Roki, None.. A. Sigler, None.. D. M. Suissa, None.. H. Eyvani, None.. G. E. Sandusky, None.. R. Khurana, None.. Y. Guo, None.. M. Dalzell, None.. S. S. Mayengbam, None.. P. Dey, None.. C. Rafie, None.. E. Stelekati, None.. J. Datta, None.. S. S. Khumukcham, None.. J. Roper, None.. N. Paluvoi, None.. S. Satta, None.. D. Bilbao Cortes, None.. A. Villarino, None.. K. Van der Jeught, None.

在会议检索中打开